Additionally, Rb-independent effects of CDK4/6 inhibitors—such as blocking phosphorylation of FOXM1 and FOXO3—further compromise DNA repair capacity post-chemotherapy or radiotherapy across diverse tumor types (Hashizume et al., 2016). The gene discussed is CDK4; the disease is neoplasm.